Saudi Researcher at Harvard University Discovers Uses of Sugammadex to Reverse Neuromuscular Blockade via Non-Surgery

A seal hangs over a building at Harvard University in Cambridge, Massachusetts November 16, 2012. REUTERS/Jessica Rinaldi/File

Dr. Shaima Al-Zaidi, a scholarship student from the Faculty of Pharmacy at Taif University, conducted a critical care research study during her Harvard University residency, SPA said on Sunday.
The study found that using “Sugammadex” effectively reverses neuromuscular blockade outside surgical operations.
In a statement to the Saudi Press Agency(SPA), Dr. Shaima said that the drug “Sugammadex” was approved by the US Food and Drug Administration in 2015 for use in surgical operations. She and her research team evaluated the uses of Sugammadex outside operating rooms and disseminated medical practices at Burgham Hospital, the second-largest teaching hospital at Harvard Medical School and the largest hospital in the Longwood Medical Area in Boston, Massachusetts.
The research has been accepted for presentation at the Critical Care Medical Conference, and the results will be published in Arizona in January 2024.
Dr. Shaima also praised the hospital for its excellence, citing how it provided her with opportunities to learn about the latest medical experiments in creating various medicines, thereby enhancing her experience. She expressed gratitude to the Saudi leadership for investing in human resources by enrolling professionals from renowned international universities across different specialties.
Dr. Shaimaa was honored with the Scientific Excellence Award and graduated among the first in the professional Ph.D. program in pharmacy at the Medical University of South Carolina. Subsequently, she joined the general pharmacy residency program at Brigham Hospital, affiliated with Harvard Medical University. Currently, she is completing a specialty residency program in critical care at the same hospital.